Immix Biopharma
IMMX
9.49
-0.15
-1.56%
Immix Biopharma
US · IMMX
#3426 by market cap
Listed 2021
9.49
-0.15
-1.56%
Live - 5344 symbols - heartbeat 458s ago
· 2026-10-08 09:01
Pre-market
9.42
-0.78%
After-hours
9.49
0.00%
- Market cap
- 788.42M
- P/E (TTM)i
- -10.78
- P/Bi
- 3.44
- EPSi
- -0.89
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on IMMX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 6 analysts
Buy
Avg price target
25.67 +170.5%
Price target rangecurrent 9.49
Low19.00
Avg25.67
High30.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-03 | LifeSci Capital | -- | BUY | 24.00 |
| 2026-09-30 | Mizuho Securities | -- | BUY | 26.00 |
| 2026-09-29 | LifeSci Capital | -- | BUY | 24.00 |
| 2026-09-29 | BofA Securities | -- | BUY | 30.00 |
| 2026-09-29 | Needham | -- | BUY | 30.00 |
| 2026-09-17 | Mizuho Securities | -- | BUY | 26.00 |
| 2026-09-15 | Mizuho Securities | -- | BUY | 26.00 |
| 2026-09-12 | LifeSci Capital | -- | BUY | 26.00 |
| 2026-09-10 | LifeSci Capital | -- | BUY | 26.00 |
| 2026-08-14 | BofA Securities | -- | BUY | -- |
| 2026-08-12 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-08-11 | Morgan Stanley | -- | BUY | 19.00 |
| 2026-08-10 | Needham | -- | BUY | 21.00 |
| 2026-08-10 | H.C. Wainwright | -- | BUY | 25.00 |
| 2026-07-22 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-07-22 | Needham | -- | BUY | 21.00 |
| 2026-06-18 | BofA Securities | -- | BUY | 27.00 |
| 2026-06-17 | LifeSci Capital | -- | BUY | 19.00 |
| 2026-05-26 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-05-22 | H.C. Wainwright | -- | BUY | 20.00 |
| 2026-04-23 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-03-30 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-03-27 | Mizuho Securities | -- | BUY | 15.00 |
| 2026-03-27 | H.C. Wainwright | -- | BUY | 15.00 |
| 2026-03-26 | Morgan Stanley | -- | BUY | 20.00 |
Price target trend monthly average, last 3 years
Quote time 2026-10-08 09:01:25 · For reference only, not investment advice and not tailored to your situation.